Small dense LDL: An emerging risk factor for cardiovascular disease

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 215-224

  Hirayama, Satoshi ^a   Miida, Takashi ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; LDL subclasses; Metabolic syndrome; Small dense LDL; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DENATURING GRADIENT GEL ELECTROPHORESIS; DENSITY GRADIENT CENTRIFUGATION; DRUG EFFECT; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GEL ELECTROPHORESIS; HEALTH CARE PLANNING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PHOTON CORRELATION SPECTROSCOPY; PRECIPITATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUBE GEL ELECTROPHORESIS; ULTRACENTRIFUGATION; ANIMAL; BLOOD; METABOLISM; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; RISK FACTORS;

EID: 84867292793     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.09.010     Document Type: Review

References (86)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106 (2002), 3143–3421.
2. Prospective Studies Collaboration, Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007), 1829–1839.
3. Mills, E.J., Rachlis, B., Wu, P., Devereaux, P.J., Arora, P., Perri, D., Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52 (2008), 1769–1781.
4. Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
5. Cannon, C.P., Steinberg, B.A., Murphy, S.A., Mega, J.L., Braunwald, E., Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006), 438–445.
6. Afilalo, J., Majdan, A.A., Eisenberg, M.J., Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93 (2007), 914–921.
7. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., Witztum, J.L., Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989), 915–924.
8. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005), 1685–1695.
9. Berneis, K.K., Krauss, R.M., Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002), 1363–1379.
10. Rizzo, M., Berneis, K., The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 20 (2006), 205–217.
11. Rizzo, M., Berneis, K., Low-density lipoprotein size and cardiovascular risk assessment. QJM 99 (2006), 1–14.
12. Packard, C., Caslake, M., Shepherd, J., The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74:Suppl. 1 (2000), S17–S22.
13. Packard, C.J., Shepherd, J., Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997), 3542–3556.
14. Ensign, W., Hill, N., Heward, C.B., Disparate LDL, phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52 (2006), 1722–1727.
15. Gofman, J.W., Lindgren, F.T., Elliott, H., Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem 179 (1949), 973–979.
16. Havel, R.J., Eder, H.A., Bragdon, J.H., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955), 1345–1353.
17. Krauss, R.M., Lindgren, F.T., Ray, R.M., Interrelationships among subgroups of serum lipoproteins in normal human subjects. Clin Chim Acta 104 (1980), 275–290.
18. Shen, M.M., Krauss, R.M., Lindgren, F.T., Forte, T.M., Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 22 (1981), 236–244.
19. Krauss, R.M., Burke, D.J., Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23 (1982), 97–104.
20. Swinkels, D.W., Hak-Lemmers, H.L., Demacker, P.N., Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. L Lipid Res 28 (1987), 1233–1239.
21. Griffin, B.A., Caslake, M.J., Yip, B., Tait, G.W., Packard, C.J., Shepherd, J., Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83 (1990), 59–67.
22. Krauss, R.M., Blanche, P.J., Detection and quantitation of LDL subfractions. Curr Opin Lipidol 3 (1992), 377–383.
23. Griffin, B.A., Freeman, D.J., Tait, G.W., Thomson, J., Caslake, M.J., Packard, C.J., et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106 (1994), 241–253.
24. Davies, I.G., Graham, J.M., Griffin, B.A., Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation. Clin Chem 49 (2003), 1865–1872.
25. Yee, M.S., Pavitt, D.V., Tan, T., Venkatesan, S., Godsland, I.F., Richmond, W., et al. Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. J Lipid Res 49 (2008), 1364–1371.
26. Austin, M.A., Breslow, J.L., Hennekens, C.H., Buring, J.E., Willett, W.C., Krauss, R.M., Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988), 1917–1921.
27. Austin, M.A., Brunzell, J.D., Fitch, W.L., Krauss, R.M., Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 10 (1990), 520–530.
28. Williams, P.T., Vranizan, K.M., Krauss, R.M., Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. J Lipid Res 33 (1992), 765–774.
29. Hoefner, D.M., Hodel, S.D., O'Brien, J.F., Branum, E.L., Sun, D., Meissner, I., et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47 (2001), 266–274.
30. Bañuls, C., Bellod, L., Jover, A., Martínez-Triguero, M.L., Víctor, V.M., Rocha, M., et al. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin Chim Acta 413 (2012), 251–257.
31. Otvos, J.D., Jeyarajah, E.J., Bennett, D.W., Krauss, R.M., Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38 (1992), 1632–1638.
32. Witte, D.R., Taskinen, M.R., Perttunen-Nio, H., Van Tol, A., Livingstone, S., Colhoun, H.M., Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res 45 (2004), 1069–1076.
33. Okazaki, M., Usui, S., Ishigami, M., Sakai, N., Nakamura, T., Matsuzawa, Y., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 25 (2005), 578–584.
34. Hirano, T., Ito, Y., Saegusa, H., Yoshino, G., A novel and simple method for quantification of small, dense LDL. J Lipid Res 44 (2003), 2193–2201.
35. Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 24 (2004), 558–563.
36. Hirayama, S., Soda, S., Ito, Y., Matsui, H., Ueno, T., Fukushima, Y., et al. Circadian change of serum concentration of small dense LDL-cholesterol in type 2 diabetic patients. Clin Chim Acta 411 (2010), 253–257.
37. Ito, Y., Fujimura, M., Ohta, M., Hirano, T., Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 57 (2011), 57–65.
38. Fukushima, Y., Hirayama, S., Ueno, T., Dohi, T., Miyazaki, T., Ohmura, H., et al. Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clin Chim Acta 412 (2011), 1423–1427.
39. Caulfield, M.P., Li, S., Lee, G., Blanche, P.J., Salameh, W.A., Benner, W.H., et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 54 (2008), 1307–1316.
40. Musunuru, K., Orho-Melander, M., Caulfield, M.P., Li, S., Salameh, W.A., Reitz, R.E., et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 29 (2009), 1975–1980.
41. O'Neal, D., Harrip, P., Dragicevic, G., Rae, D., Best, J.D., A comparison of LDL size determination using gradient gel electrophoresis and light-scattering methods. J Lipid Res 9 (1998), 2086–2090.
42. Sakurai, T., Trirongjitmoah, S., Nishibata, Y., Namita, T., Tsuji, M., Hui, S.P., et al. Measurement of lipoprotein particle sizes using dynamic light scattering. Ann Clin Biochem 47 (2010), 476–481.
43. Musliner, T.A., McVicker, K.M., Iosefa, J.F., Krauss, R.M., Metabolism of human intermediate and very low density lipoprotein subfractions from normal and dysbetalipoproteinemic plasma. In vivo studies in rat. Arteriosclerosis 7 (1987), 408–420.
44. Krauss, R.M., Williams, P.T., Lindgren, F.T., Wood, P.D., Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men. Arteriosclerosis 8 (1988), 155–162.
45. Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E., Ahfeldt, T., Sachs, K.V., et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466 (2010), 714–719.
46. Strong, A., Rader, D.J., Sortilin as a regulator of lipoprotein metabolism. Curr Atheroscler Rep 14 (2012), 211–218.
47. Anber, V., Griffin, B.A., McConnell, M., Packard, C.J., Shepherd, J., Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124 (1996), 261–271.
48. Griffin, B.A., Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 58 (1999), 163–169.
49. Goulinet, S., Chapman, M.J., Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17 (1997), 786–796.
50. Tribble, D.L., Rizzo, M., Chait, A., Lewis, D.M., Blanche, P.J., Krauss, R.M., Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110 (2001), 103–110.
51. Younis, N., Charlton-Menys, V., Sharma, R., Soran, H., Durrington, P.N., Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 202 (2009), 162–168.
52. Soran, H., Durrington, P.N., Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 22 (2011), 254–261.
53. Matsui, H., Okumura, K., Toki, Y., Hayakawa, T., Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level. Diabetes Care 22 (1999), 1220–1221.
54. Younis, N.N., Soran, H., Sharma, R., Charlton-Menys, V., Greenstein, A., Elseweidy, M.M., et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 7 (2010), 289–295.
55. Miller, Y.I., Choi, S.H., Wiesner, P., Fang, L., Harkewicz, R., Hartvigsen, K., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 108 (2011), 235–248.
56. Tsimikas, S., Miller, Y.I., Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 17 (2011), 27–37.
57. Rizzo, M., Rini, G.B., Spinas, G.A., Berneis, K., The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?. Atherosclerosis 204 (2009), 330–333.
58. Toledo, F.G., Sniderman, A.D., Kelley, D.E., Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29 (2006), 1845–1850.
59. Cali, A.M., Zern, T.L., Taksali, S.E., de Oliveira, A.M., Dufour, S., Otvos, J.D., et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care 30 (2007), 3093–3098.
60. Makimura, H., Feldpausch, M.N., Stanley, T.L., Sun, N., Grinspoon, S.K., Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin Endocrinol (Oxf) 76 (2012), 220–227.
61. Pirwany, I.R., Fleming, R., Greer, I.A., Packard, C.J., Sattar, N., Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54 (2001), 447–453.
62. Doi, S.A., Abbas, J.M., Parkinson, L., Chakraborty, J., Akanji, A.O., LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome. Am J Clin Pathol 129 (2008), 802–810.
63. Phelan, N., O'Connor, A., Kyaw-Tun, T., Correia, N., Boran, G., Roche, H.M., et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 95 (2010), 3933–3939.
64. Vinaixa, M., Rodriguez, M.A., Samino, S., Díaz, M., Beltran, A., Mallol, R., et al. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS One, 6, 2011, e29052.
65. Sopkova Z, Berneis K, Rizzo M, Spinas GA, Dorkova Z, Tisko R, Tkacova R. Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea. angiology in press (published on line 20 Jan 2012), http://dx.doi.org/10.1177/0003319711433811.
66. Luyster, F.S., Kip, K.E., Drumheller, O.J., Rice, T.B., Edmundowicz, D., Matthews, K., et al. Sleep apnea is related to the atherogenic phenotype, lipoprotein subclass B. J Clin Sleep Med 8 (2012), 155–161.
67. Bucher, H.C., Richter, W., Glass, T.R., Magenta, L., Wang, Q., Cavassini, M., et al. Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 60 (2012), 135–142.
68. Badiou, S., Merle De Boever, C., Dupuy, A.M., Baillat, V., Cristol, J.P., Reynes, J., Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?. Atherosclerosis 168 (2003), 107–113.
69. Badiou, S., Merle De Boever, C., Dupuy, A.M., Baillat, V., Cristol, J.P., Reynes, J., Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 172 (2004), 273–279.
70. Kim YK, Seo HS, Lee EM, Na JO, Choi CU, Lim HE, Kim EJ, Rha SW, Park CG, Oh DJ. Association of hypertension with small, dense low-density lipoprotein in patients without metabolic syndrome. J Hum Hypertens in press; http://dx.doi.org/10.1038/jhh.2011.86.
71. Badiou, S., Garrigue, V., Dupuy, A.M., Chong, G., Cristol, J.P., Mourad, G., Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?. Transplant Proc 38 (2006), 2314–2316.
72. Zeljkovic, A., Vekic, J., Spasojevic-Kalimanovska, V., Jelic-Ivanovic, Z., Peco-Antic, A., Kostic, M., et al. Characteristics of low-density and high-density lipoprotein subclasses in pediatric renal transplant recipients. Transpl Int 24 (2011), 1094–1102.
73. Karalis, D.G., Ishisaka, D.Y., Luo, D., Ntanios, F., Wun, C.C., Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 100 (2007), 445–449.
74. Ai, M., Otokozawa, S., Asztalos, B.F., Nakajima, K., Stein, E., Jones, P.H., et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101 (2008), 315–318.
75. Nozue, T., Michishita, I., Ito, Y., Hirano, T., Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 15 (2008), 146–153.
76. Tokuno, A., Hirano, T., Hayashi, T., Mori, Y., Yamamoto, T., Nagashima, M., et al. The effects of statin and fibrate on lowering small dense LDL‐cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb 14 (2007), 128–132.
77. Bahadir, M.A., Oguz, A., Uzunlulu, M., Bahadir, O., Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 16 (2009), 684–690.
78. Leonhardt, W., Pfützner, A., Müller, J., Pietzsch, J., Forst, T., Karagiannis, E., et al. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis 201 (2008), 155–162.
79. Zhang, B., Matsunaga, A., Rainwater, D.L., Miura, S., Noda, K., Nishikawa, H., et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. J Lipid Res 50 (2009), 1832–1841.
80. Azar, R.R., Badaoui, G., Sarkis, A., Azar, M., Aydanian, H., Harb, S., et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 106 (2010), 193–197.
81. Winkler, K., Jacob, S., Müller-Schewe, T., Hoffmann, M.M., Konrad, T., Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220 (2012), 189–193.
82. Ai, M., Otokozawa, S., Asztalos, B.F., Ito, Y., Nakajima, K., White, C.C., et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 56 (2010), 967–976.
83. Miida, T., Otsuka, H., Tsuchiya, A., Okada, M., Plasma lipoprotein profiles change significantly during cardiac catheterization. Clin Chem 44 (1998), 517–521.
84. Ip, S., Lichtenstein, A.H., Chung, M., Lau, J., Balk, E.M., Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 150 (2009), 474–484.
85. NACB LMPG Committee Members, Myers, G.L., Christenson, R.H., Cushman, M., Ballantyne, C.M., Cooper, G.R., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 55 (2009), 378–384.
86. Bays, H., Conard, S., Leiter, L.A., Bird, S., Jensen, E., Hanson, M.E., et al. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids Health Dis, 9, 2010, 136.